



GlaxoSmithKline  
7890 Charline Court  
Lewis Center, OH 43035  
Tel. 740 549-2426  
[www.gsk.com](http://www.gsk.com)

February 14, 2007

The Honorable Paul Condino, Chairman  
House Judiciary Committee  
State Representative  
State Capitol  
P.O. Box 30014  
Lansing, MI 48909-7514

Subject: House Bills 4044, 4045, and 4046

Dear Representative Condino:

I ask you and the House Judiciary Committee to vote against House Bills 4044, 4045, and 4046. By doing so, you will help to preserve the many life enhancing, and life saving benefits of new and improved medicines for your constituents.

Each year, GlaxoSmithKline (GSK) and other research-based pharmaceutical companies invest billions of research dollars in search of medicines that can meet Food and Drug Administration standards of safety, and effectiveness. Last year, GSK alone invested more than \$865,000 in medical research that was conducted by Michigan-based institutions.

In return for meeting the FDA's rigorous national standards, manufacturers are protected by current law from litigation. HB4044, 45, and 46 would serve to remove manufacturers' protections, to increase the risk of unacceptable litigation, and to discourage huge investments in future medical research. Thousands of your constituents benefit from today's medicines. How many will suffer from a shortage of future life-saving medicines?

Last year, thousands of Michigan citizens benefited from the \$15 million that GSK provided in patient assistance last year. Can you imagine how many of your constituents benefited from the pharma industry's collective investment in Michigan's economy? Please vote against these bills that would put a chill on investments that help so many.

Yours truly,


A handwritten signature in black ink, appearing to read "Charles G. Williams".

Charles G. Williams, Director  
State Government Affairs

# STATE Investing

REVIEW OF ECONOMIC CONTRIBUTIONS  
IN YOUR STATE

2006



## GlaxoSmithKline Investing in Michigan

GlaxoSmithKline (GSK) is a world-leading research-based pharmaceutical company whose mission is to improve the quality of human life by enabling people to do more, feel better and live longer. Operations of GSK circle the globe and address a common purpose: providing innovative medicines and services that prevent and treat disease. True to that mission, GSK scientists and other employees are searching for new and better treatments for a variety of diseases. GSK's research and development expenditures worldwide total \$5.6 billion annually. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products, and nutritional health products, all of which are among the market leaders. GSK has US headquarters in Philadelphia, PA and Research Triangle Park, NC as well as employees in all 50 states.

Being a good corporate citizen is one of GSK's key priorities. Committed to the communities in which we work around the country, our charitable and community programs support projects that are innovative, sustainable, and focused on producing tangible results. GSK will continue to build on these foundations of wide-ranging philanthropic support, which reflects its position as one of the largest research-based pharmaceutical companies in the world.

### ECONOMIC CONTRIBUTIONS IN MICHIGAN

<b>Clinical Grants</b>	<b>\$865,636</b>
<b>Patient Assistance Program</b>	<b>\$15,068,794</b>
<b>Corporate Contributions</b>	<b>\$840,483</b>
<b>Taxes Paid</b>	<b>\$3,073,258</b>
<b>Total Business Expenditures*</b>	<b>\$136,877,052</b>

### EMPLOYMENT

Michigan	376
United States	24,947
Worldwide	110,000

### WORLDWIDE RESEARCH AND DEVELOPMENT INVESTMENTS \$5.6 billion annually

### PHARMACEUTICAL AREAS

Anti-infectives	Depression
Asthma	Diabetes
Cancer	HIV-AIDS
Cardiovascular	Migraine
COPD	Osteoporosis

### VACCINES

DTaP	Influenza
Hepatitis A	Polio
Hepatitis B	Tdap

### CONSUMER HEALTHCARE AREAS

Dermatology	Gastrointestinal
Nutrition	Oral Health
Smoking Cessation	Vitamins & Naturals

\*Includes rebates, employee costs,  
and other business expenses

All figures are for 2005.

A Publication of GlaxoSmithKline Public Policy and Advocacy



GlaxoSmithKline